SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
[November 07, 2018]

Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference


ALPHARETTA, Ga., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its Chief Executive Officer and President, Daniel White, will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 11:45 a.m. ET at the Lotte New York Palace Hotel .

A live webcast of the presentation can be accessed on the company’s website at www.clearsidebio.com under the “Events & Presentations” tab in the “Investor Relations” section.  Following the conference, the presentation webcast will be archived on the website for 30 days.

About Clearside

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases.  Clearside’s proprietary supachoroidal treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs.  The company’s unique platform for eye disease treatments is inherently flexible and intended to work with established medicines, new formulations of medicines, as well as future innovations.  Clearside’s pipeline includes advanced and preclinical product candidates for serious eye diseases, including uveitis and diabetic macular edema (“DME”).  Clearside’s most advanced program is in non-infectious uveitis and it expects to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for XIPERE™ (formerly “suprachoroidal CLS-TA”) for the treatment of macular edema associated with non-infectious uveitis by the end of 2018.  In addition, Clearside recently announced positive topline results from a Phase 2 clinical trial of XIPERE used with EYLEA® (aflibercept) in patients with DME.  Clearside is headquartered in Alpharetta, GA.  For more information, please visit http://www.clearsidebio.com.  Follow @clearsidebio on Twitter and Linkedin.



Contacts:

Stephen Kilmer
Investor Relations
(678) 430-8206
stephen.kilmer@clearsidebio.com


Charles Deignan
Chief Financial Officer
(678) 270-4005
charlie.deignan@clearsidebio.com

 

logo color s and clearside.jpg


[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy